腎移植後de novo悪性腫瘍

書誌事項

タイトル別名
  • De novo malignancy after kidney transplantation

説明

<p>Kidney transplantation is improving quality of life as well as life expectancy. However, immunosuppressive drugs after kidney transplantation are increasing the standardized incidence ratio and cumulative incidence of malignant tumors. Malignancies have also recently become the leading cause of death among kidney transplant recipients. In recent years, the frequency of malignancy is increasing due to the long-term viability and survival of kidney transplant recipients and the increasing potency of immunosuppressive drugs. Malignancy control is needed to further improve the outcome of kidney transplantation. In this article, we would like to clarify the characteristics, screenings and managements of de novo malignancy after kidney transplantation.</p>

収録刊行物

  • 移植

    移植 59 (2), 157-165, 2024

    一般社団法人 日本移植学会

詳細情報 詳細情報について

  • CRID
    1390865286992296192
  • DOI
    10.11386/jst.59.2_157
  • ISSN
    21880034
    05787947
  • 本文言語コード
    ja
  • データソース種別
    • JaLC
  • 抄録ライセンスフラグ
    使用不可

問題の指摘

ページトップへ